Cargando…

MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data

SIMPLE SUMMARY: The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating cell proliferation, differentiation and survival. Overexpression and overactivation of members within the signaling cascade have been observed in many solid cancers and especially in thyroid cancers. These members ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schubert, Louis, Mariko, Mohamed Lamine, Clerc, Jérôme, Huillard, Olivier, Groussin, Lionel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913385/ https://www.ncbi.nlm.nih.gov/pubmed/36765665 http://dx.doi.org/10.3390/cancers15030710

Ejemplares similares

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers
por: Buffet, Camille, et al.
Publicado: (2017)

Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma
por: Paepegaey, Anne-Cécile, et al.
Publicado: (2017)

In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies
por: Simeonova, Iva, et al.
Publicado: (2014)

MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer
por: Garcia, Cyril, et al.
Publicado: (2019)

NF-κB signaling activation and roles in thyroid cancers: implication of MAP3K14/NIK
por: Cormier, Françoise, et al.
Publicado: (2023)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Bellesoeur, Audrey, et al.
Publicado: (2017)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone but decide wisely
por: Huillard, Olivier, et al.
Publicado: (2020)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
por: Laetitia, Gheysen, et al.
Publicado: (2020)

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer
por: Pozo, Karine, et al.
Publicado: (2018)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
por: Ma, Pengfei, et al.
Publicado: (2016)

Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies
por: Krashin, Eilon, et al.
Publicado: (2019)

Checkpoint inhibitors in ovarian cancer: A review of preclinical data
por: Doo, David W., et al.
Publicado: (2019)

Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway
por: Wang, Shunde, et al.
Publicado: (2018)

Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data
por: Sigorski, Dawid, et al.
Publicado: (2020)

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
por: Eldar-Finkelman, Hagit, et al.
Publicado: (2011)

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors
por: Delmas, Audrey, et al.
Publicado: (2015)

Borealin/CDCA8 deficiency alters thyroid development and results in papillary tumor-like structures
por: Didier-Mathon, Hortense, et al.
Publicado: (2023)

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
por: Enomoto, Keisuke, et al.
Publicado: (2021)

Metastasis and MAPK Pathways
por: Kciuk, Mateusz, et al.
Publicado: (2022)

MAPK-ERK Pathway
por: Park, Jong-In
Publicado: (2023)

MAPK Pathway Inhibitors Attenuated Hydrogen Peroxide Induced Damage in Neural Cells
por: Fan, Zhenwei, et al.
Publicado: (2019)

V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results
por: Devillier, Philippe, et al.
Publicado: (2015)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion
por: Hughes, Veronica S., et al.
Publicado: (2019)

Downregulation of BANCR Promotes Aggressiveness in Papillary Thyroid Cancer via the MAPK and PI3K Pathways
por: Zhang, Jinjun, et al.
Publicado: (2018)

Asporin Interacts With HER2 to Promote Thyroid Cancer Metastasis via the MAPK/EMT Signaling Pathway
por: Zhan, Shaohua, et al.
Publicado: (2022)

Comparative Preclinical Study of Lidocaine and Mepivacaine in Resilient Hyaluronic Acid Fillers
por: Brusini, Romain, et al.
Publicado: (2022)

7-Ketocholesterol enhances leukocyte adhesion to endothelial cells via p38MAPK pathway
por: Tani, Mariko, et al.
Publicado: (2018)

Hyperthyroxinaemia in hepatocellular carcinoma: relation to thyroid binding globulin in the clinical and preclinical stages of the disease.
por: Alexopoulos, A., et al.
Publicado: (1988)

Effects of roniciclib in preclinical models of anaplastic thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer
por: Greco, Adelaide, et al.
Publicado: (2017)

Reversal of a Blunted Follicle-Stimulating Hormone by Chemotherapy in an Inhibin B–Secreting Adrenocortical Carcinoma
por: Espiard, Stéphanie, et al.
Publicado: (2017)

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
por: Huillard, Olivier, et al.
Publicado: (2019)

Aberrant MRP14 expression in thyroid follicular cells mediates chemokine secretion through the IL-1β/MAPK pathway in Hashimoto’s thyroiditis
por: Luo, Xuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vk69sbc25svlva446d3f6otk3v